Kirin-amgen, Inc.

Rika Ishikawa

Makoto Kakitani

Yuji Okada

The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: (Het)n - Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln - Ser Phe Leu Leu Lys Cys Leu Glu Gln Val Arg - Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu - Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro - Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly - Ile Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser - Gln Ala Leu Gln Leu Ala Cly Cys Leu Ser Gln - Leu His Ser Gly Leu Phe Leu Tyr Gln GIY Leu - Leu Gln Ala Leu Glu Gly Ile Ser Pro Glu Leu - Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val - Ala Asp Phe Ala Thr Tbr Ile Trp Gln Gln Het - Glu Glu Leu Gly Het Ala Pro Ala Leu Gln Pro - Thr Gln Gly Ala Het Pro Ala Phe Ala Ser Ala - Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala - Ser His Leu Gln Ser Phe Leu Glu Val Scr Tyr - Arg Val Leu Arg His Leu Ala Gln Pro (n = 0 or 1) The chemically-modified protein according to the present invention has a neutrophils-increasing activity much more lasted than that of the intact human G-CSF, enabling fewer numbers of administration with a lower dose.

Chemically-modified G-CSF

The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: ##STR1## The chemically-modified protein according to the present invention has a much longer lasting neutrophil-increasing activity than that of the intact human G-CSF, enabling fewer numbers of administration with a lower dose.

Growing community of inventors

Higashiyamato, Japan

Rika Ishikawa